Welcome to the Desert Angels™. We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies. The organization serves as a forum for its over 90 members, who invest individually from their personal funds. Since 2000, Desert Angel members have invested over $32 million in more than 75 presenting companies.

More and More Students Turning to Picmonic’s Audiovisual Learning System for Improved Educational Outcomes

by gabrielsayegh on March 2nd, 2015 at 1:19am

Desert Angels portfolio company, Picmonic, shows significant growth in the medicine and nursing market as member base more than doubles.

Click here for full article.

Comment

Filed under: Uncategorized

Silicon Desert: How Phoenix is quickly — and quietly — becoming a hub for innovation

by gabrielsayegh on February 14th, 2015 at 4:40pm

As the Desert Angels partners with fellow community organizations to bring innovation to Arizona, Geekwire has noted our startup environment to ready to explode. “The current state of the startup ecosystem in [Arizona] is like a popcorn bag that’s spent 60 seconds inside a hot microwave. One minute has passed, but only a few pops are audible. Soon, though, a flurry of kernels will heat up just enough to elicit multiple explosions all at once, joining those that have already matured into white fluff.”

Click here for full article.

Comment

Filed under: News Releases, Press

How a mutated gene receptor and stem cell technology could lead to a cure for HIV

by gabrielsayegh on February 4th, 2015 at 4:53pm

One of Desert Angels’ prominent portfolio companies, Calimmune, has announced it is about to move on to the second half of its Phase 1 human trial, and will soon implant four new patients with its genetically modified stem cells.

Click here for full article

Comment

Filed under: Funded Companies

Two Tucson firms among 6 innovation grant winners

by gabrielsayegh on February 4th, 2015 at 4:24pm

The Arizona Commerce Authority announced the six winning companies in its Fall 2014 Arizona Innovation Challenge on Tuesday, and two are from Tucson, including Desert Angels portfolio company, NuvO Pharma.

Click here for the full article

Comment

Filed under: Funded Companies

Tucson’s SynCardia wins OK for key heart study

by gabrielsayegh on January 10th, 2015 at 3:50pm

Desert Angels portfolio company, Tucson-based SynCardia Systems Inc. has received approval from the U.S. Food and Drug Administration to conduct a clinical study of the company’s temporary Total Artificial Heart for permanent use as so-called “destination therapy.” The FDA approved an Investigational Device Exemption application to allow SynCardia to study the heart’s use in 19 patients who do not qualify for a donor heart transplant.

Click here for the full article

Comment

Filed under: Funded Companies

HTG Molecular Diagnostics Files for IPO of up to $60M

by gabrielsayegh on January 7th, 2015 at 3:45pm

Desert Angels portfolio company, HTG Molecular Diagnostics, has filed a prospectus for an initial public offering of its stock for up to $60 million. The Tucson, Ariz.-based firm has not priced its shares nor said how many shares it plans to offer. It said in its Form S-1 filed with the US Securities and Exchange Commission on Tuesday that it plans to trade its stock on the Nasdaq Global Market under the ticker symbol “HTGM.” Leerink Partners, Canaccord Genuity, and JMP Securities are listed as the offering’s underwriters.

Click here for the full article.

Comment

Filed under: Funded Companies

Stimwave Receives FDA Clearance for World’s First Injectable Wireless MicroSize Pain Relief System for Chronic Back and Leg Pain

by gabrielsayegh on December 8th, 2014 at 5:28pm

Desert Angels portfolio company, Stimwave Technologies Incorporated; a medical device manufacturer and independent research institute headquartered in Miami Beach, Fla., has received FDA clearance to market the world’s first wireless, microtechnology neuromodulation device for relief of chronic back and leg pain. Currently being marketed throughout Europe, Stimwave announced it’s revolutionary electroceutical device will be commercially available in the U.S. as of January 2015.

Click here for the full article

1 comment

NuvOx Pharma Awarded $1M Grant from National Cancer Institute

by gabrielsayegh on November 12th, 2014 at 5:57pm

Desert Angels portfolio company, NuvOx Pharma; a biotechnology company based in Tucson, Arizona, has received a $1M grant from the National Cancer Institute (NCI) “Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma, (NCI Phase II SBIR, R44CA144817 – 02A1).” This grant comes less than a month after NuvOx was highlighted here for beginning Phase Ib clinical trial of its new drug — an oxygen-delivery agent — in patients with glioblastoma multiforme, a rare but particularly deadly form of brain cancer.

Click here for the full article

Comment

Filed under: Uncategorized

Picmonic receives $1.25 million in financing from local investors

by gabrielsayegh on November 12th, 2014 at 5:50pm

Desert Angels portfolio company, Picmonic; the Tempe-based company  which develops audiovisual study cards for medical students, has closed on $1.25 million in financing from local investors. Picmonic CEO and co-founder Ron Robertson said the money will help support the company’s move into the mobile industry and open up new markets in education. This financing, which closed in September, brings the company’s total money raised to $2.6 million.

Click here for the full article

Comment

Filed under: Funded Companies

Tucson Drug Startups in Key Clinical Trials

by gabrielsayegh on October 12th, 2014 at 10:53pm

Desert Angels portfolio companies, Cancer Prevention Pharmacuticals (CPP) & NuvOx Pharma (NuvOx), are in human clinical trials that could result in new drug approvals in the next few years. Both of these local startup companies are founded by University of Arizona research faculty. Local biosciences industry leaders say the companies’ progress in navigating the long and costly drug-approval process is noteworthy, as they progress through trials at the same time.

Click here for the full article

Comment

Filed under: Uncategorized